The trial is the first in the US to test the potential of niclosamide, a drug with a long history of use in treating tapeworm, for COVID-19, the disease caused by SARS-CoV-2.
Niclosamide, which is not currently available in the US, has been used for more than 50 years to treat millions of people worldwide, with its primary indication being the treatment of tapeworm infections.
The drug recently emerged as a promising candidate for treating SARS-CoV-2.
In pre-clinical research by an independent academic group published in Antimicrobial Agents and Chemotherapy, niclosamide inhibited viral replication in vitro and was more potent than remdesivir in the same assay.
The mechanism of action for niclosamide's inhibition of SARS-CoV-2 is believed to be through SKP2-inhibition.
In a preprint, an independent academic group reported niclosamide prevents SARS-CoV-2 replication via SKP2-inhibition.
The same group previously reported in Nature Communications that niclosamide prevents the replication of Middle East respiratory syndrome (MERS-CoV), a coronavirus closely related to SARS-CoV-2, by the same mechanism.
In addition to its antiviral properties, niclosamide has shown anti-inflammatory activity through NF-κB and STAT3, transcription factors that induce the expression of molecules that drive inflammation.
In vitro experiments reported in Cancer Research and ACS Medicinal Chemistry Letters, respectively, demonstrated that niclosamide inhibited both NF-κB and STAT3 transcription.
The Phase 2/3 trial is a randomized, placebo-controlled study that will be conducted in two parts at a total of 20 clinical sites in the US In both study parts, hospitalized patients with moderate COVID-19 (patients not requiring ventilators) will be administered a seven-day course of niclosamide capsules in addition to standard of care.
The primary objective of the first part of the trial is assess safety and tolerability; secondary objectives include measurement of efficacy (median time to discharge) and pharmacokinetics.
The trial's second part will enroll several hundred patients, with the primary objectives of assessing niclosamide's efficacy (median time to hospital discharge), safety and tolerability. Secondary objectives relate to clinical improvement and the need and duration for rescue therapy.
ANA Therapeutics is a Silicon Valley-based biotech start-up developing a proprietary niclosamide formulation as a widely accessible antiviral treatment for patients with COVID-19. ANA Therapeutics is the first Y Combinator portfolio company to initiate a Phase 2 clinical trial.
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
CLS secures second order from NIH Clinical Center for Thermal Therapy System accessories